EP

Eirini Panagiotopoulou

Formulation Scientist at Custom Pharma Services

Eirini Panagiotopoulou is a skilled formulation scientist currently working at Custom Pharma Services since October 2021. Prior experience includes roles as a research and development scientist at RAFARM S.A from February 2018 to May 2021, a quality assurance officer at Elliniki Agora Kreatwn from 2015 to 2017, a research chemist at Eldrug from 2013 to 2014, and a chemistry teacher at a secondary school from 2012 to 2013. Eirini holds a Master's Degree in Medicinal and Pharmaceutical Chemistry and a Bachelor's Degree in Chemistry, both obtained from the University of Patras, with the latter completed in 2010 and the former in 2014.

Location

Brighton, United Kingdom

Links


Org chart

No direct reports

Teams

This person is not in any teams


Offices


Custom Pharma Services

1 followers

Custom Pharma Services is located in Brighton, UK since 1979 and is a full-service contract development and manufacturing organisation (CDMO) providing services tailored to your needs, no matter how niche or complex. Custom covers the full spectrum of activities from development through commercial manufacturing for both clinical and commercial use. Specialising in Oral Solid Dosage forms with the ability to handle highly potent drugs and poorly bioavailable compounds Custom really is your one stop resource. With direct access to highly skilled experts offering a partnership approach Custom Pharma Services truly has a molecule first mentality, managing all projects with the end in mind. Custom Can! • Custom Pharma is a CDMO offering clinical and commercial manufacturing of tablets, capsules, powders (oral-solid-dose) for human use. • Services comprise pre-formulation and formulation development, analytical development, stability testing, clinical trial material manufacturing • Commercial Production • Pre-clinical formulation development and solubilisation • Material characterisation • Drug in capsule approach to accelerate early clinical studies • Specialists in low dosage (sub-mg) formulations • Contained manufacturing for highly potent APIs • Orphan drug development • Formulation development of poorly soluble drugs, including spray drying capabilities


Employees

51-200

Links